エピソード
-
Genitourinary Cancers dominated ASCO24 this year, and Josh and Michael's ASCO Odyssey needed two episodes to fit it all in. Join them as they board the Nautilus with Captain Nemo in search of the best trials to propel bladder and renal cancer to the forefront of your mind. This episode covers both the use of perioperative sacituzumab govitecan, avelumab as neoadjuvant therapy for bladder cancer and camrelizumab for previously treated advanced adrenocortical carcinoma. Not to be forgotten, they explore a biomarker analysis of the CLEAR trial to see whether any treasure is to be found...
Links to studies discussed in this episode (subscription may be required)
SURE 01/02: Link
AURA: Link
CLEAR biomarker analysis: Link
Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
The Star Spangled Banner courtesy of Music_Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Unbeknownst to Josh, we are already at Day 5 of our ASCO Odyssey, and like Odysseus arriving at Circe's island of Aeaea, we have arrived at the episode devoted to early Breast Cancer. Today we examine four very interesting studies, looking at alternative immunotherapy strategies with adjuvant avelumab, adjuvant endocrine therapy omission in low-ER positive disease, ctDNA in predicting disease recurrence, and a study that aims to change the very bedrock of breast cancer classification. Lots to discuss, deconstruct and debate on today's episode!
Links to studies discussed (subscription may be required):
A-BRAVE: Link
Adjuvant ET omission in ER-low patients: Link
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC): Link
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
エピソードを見逃しましたか？
-
Today, Michael and Josh approach a singular destiny to present their take on Metastatic Breast Cancer at ASCO 2024. Long has Breast Cancer been one of the most diagnosed cancers globally; these days, it leads the herd with effective treatment options and paradigm shifts that benefit millions of people on a massive scale. With CDK4/6 inhibitors, immunotherapy and antibody-drug conjugates, the arsenal of effective treatment tools continues to grow! Nothing excites an oncologist more than a good randomised phase 3 international study. Today, they present the following:
Links to studies discussed (subscription may be required):
Destiny-Breast06: Link
postMONARCH: Link
INAVO120: Link
OptiTROP-Breast01: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Day 3 of Oncology for the Inquisitive Mind's ASCO Odyssey and our hosts show no sign of flagging under this immense pressure, although Josh has started to give up on his famous segues. In this episode, our intrepid hosts tackle gynaecological cancers, reporting on four of their favourite studies from a packed field of gynaecological cancers. Will new treatment options for cervical cancer emerge? Will the sugical approach to recurrent ovarian cancer change? Is there still a place for single agent olaparib in the management of ovarian cancers? Listen on to find out.
Links to studies discussed in this episode (subscription may be required):
Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study: Link
AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer: Link
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial: Link
Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
The Star Spangled Banner courtesy of Music_Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
As the sun rises on another day at ASCO, Michael and Josh are ready to hit the ground running to bring you the latest and greatest in all things oncology in Chicago has to offer. No greek mythology today, only a burning desire to bring you the biggest melanoma trials from ASCO24. Today, they pack a punch, tackling some intriguing phase 1 trials with tongue-twisting names where the novelty wears off pretty quickly!
Links to articles discussed in this episode (subscription may be required):
RELATIVITY-048: link
SX-682: link
PIVOTAL: link
BRENETAFUSP: link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
"Tell me, Muse, the story of that resourceful man who was driven to wander far and wide after he had sacked Troy. He saw the cities of many people and he learnt their ways. Tell us this story, goddess daughter of Zeus, beginning at whatever point you will." So begins Homer's epic The Odyssey, the story of the titular hero Odysseus' long, long, LONG journey from the ruins of Troy to his home of Ithaca. Just as Odysseus set out from Troy, so do Michael and Josh begin an "odyssey" of their own. The American Society of Clinical Oncology's 2024 meeting is in full swing, bringing a veritable Charybdis of content into the world of medical oncology. The starting point for this epic journey is updates to non-small cell lung cancer, including a new contender for our hosts' favourite study of all time.
Links to articles discussed in this episode (subscription may be required):
EVOKE-1: Link
ICARUS-LUNG01: Link
CROWN 5-year update: Link
HARMONI-A: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
The Star Spangled Banner courtesy of Music_Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
With ASCO upon us, Michael and Josh squeeze one more episode of their regular schedule to bring you an important update on gastric cancer. For context, the 5 year survival rate for metastatic gastric cancer is 6%, similar to that of pancreatic cancer. Despite improvement in survival due to the addition of nivolumab to chemotherapy (Checkmate 64), few therapies have significantly changed it's overall prognosis.
This week Michael and Josh explore the addition of a LAG-3 inhibitor (relatlimab) to the SOC nivolumab and chemotherapy to see if gastric cancers fortune may change. Synergistic evidence has been seen in melanoma, but melanoma has a completely different biology.. Michael engages with Keynote-811, the addition of trastuzumab to SOC chemotherapy for hER2 positive metastatic gastric/GOJ cancer. Is this HER2 antibody strong enough to stop this cancers march?
Tune in today, and for the forseeable future and Josh and Michael go where no podcaster has gone before--->
Links to articles discussed in this episode (subscription may be required):
Relativity 060: Link
Keynote 811: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Oncology research never sits still, nor does the desire for better treatment options for metastatic colorectal cancer. Fifty percent of diagnosed cases develop metastatic spread during their disease course. This week, we look for the "SUNLIGHT" and investigate the combination of Lonsurf with Bevacizumab and using Fruquintinib with refractory metastatic colorectal cancer.
Links to articles discussed in this episode (subscription may be required):
FRESCO-2: Link
SUNLIGHT: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections.
This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discussed: The first is HIMALAYA comparing durvalumab and tremelimumab versus the old incumbent sorafenib (tyrosine kinase inhibitor). Will immunotherapy take the reigns as the preferred agents? Our second study is Compassion-08, (Michael has an abundance of this). The trial is unique as it involves a first-in-class bispecific antibody targeting PD-1 and CTLA-4 (cadonilimab in combination with lenvatinib).
Interesting times ahead in the HCC space
Links to articles discussed in this episode (subscription may be required):
HIMALAYA: Link
COMPASSION-08: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
In many parts of the world, Bevacizumab is an important component of the treatment of glioblastoma, colorectal, hepatocellular and ovarian cancers. However, with such widespread use inevitably comes toxicity. Side effects related to bevacizumab are not your garden-variety chemotherapy side effects, nor are they similar to toxicity from immunotherapy. Rather, they stand apart, unique amongst our systemic therapies.
In their latest Onconack, Josh and Michael take a look at two of the most commonly described toxicities related to bevacizumab: hypertension and proteinuria. This is sure to be a valuable resource to any oncology trainee blessed (or cursed) with the unit pager!
Links to useful sources for further reading (subscription may be required):
Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials: Link
Practical Management of Bevacizumab-Related Toxicities in Glioblastoma: Link
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. Link
Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
As many philosophers have noted, life often travels in cycles. Almost two years and more than 100 episodes ago, on a virtual call far far away, two young oncologists started on a journey to bring the latest oncology evidence to anyone with ears and the will to listen. Now, for episode number 101, Josh and Michael return to where it all started: prostate cancer. Much has changed in the (nearly) two years since that episode, and so in this episode, our hosts provide an update on two more recent updates in the prostate cancer space: Michael discusses TALAPRO-2, the latest in a flurry of studies examining patients with homologous-repair-deficient prostate cancer examining enzalutamide and talazoparib. Josh presents a study close to his heart; ENZA-P is an Australian-led study combining novel anti-androgen agents with the even-more-novel radioactive agent Lutetium-PSMA. Both represent the crest of the new wave of targeted prostate cancer treatment, and there are many tidbits to be gobbled up in this, the start of a new 100 episode cycle for Oncology for the Inquisitive Mind!
Links to articles discussed in this episode (subscription may be required):
TALAPRO-2: https://www.nature.com/articles/s41591-023-02704-x
ENZA-P: https://www.sciencedirect.com/science/article/pii/S1470204524001359?dgcid=coauthor
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
For 100 episodes, Josh and Michael have brought to your ears the latest and greatest in oncology research and treatment. In this episode, we will take a trip down memory lane, speaking about our journey up to this point, our favourite guests and favourite trials, and give you a glimpse of what the future holds for Oncology for the Inquisitive Mind. If we're honest, we never expected to get this far, and we have you, our wonderful audience to thank for that. We are so grateful for your support, you are the reason we keep coming back every week to record, and we hope to continue to bring you more oncology-related goodness for many more episodes to come!
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode, Josh and Michael examine the rapidly developing world of early lung cancer treatment. An area that will hopefully only grow in importance, treatment for early NSCLC is becoming ever more sophisticated, with recent developments in neoadjuvant management and confirmation of the benefit of adjuvant driver-mutation inhibitior treatment. Today's articles cover two such topics: will osimertinib finally reach the pinnacle it was born to reach and be used in the neoadjuvant treatment of EGFR-mutant NSCLC? Will alectinib join its older, more successful cousin in being effective in resected ALK-mutant NSCLC? Listen on to find out, but we'll give you this one for free: if you have a patient with early NSCLC, it is becoming imperative that you test them for these mutations. Truly a fascinating time.
Links to articles discussed in this episode (subscription may be required):
NEOS: https://www.lungcancerjournal.info/article/S0169-5002(23)00072-7/fulltext
ALINA: https://www.nejm.org/doi/full/10.1056/NEJMoa2310532
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
On this very special episode, Josh and Michael welcome Dr Adam Brufsky, a trailblazer in the world of breast cancer treatment and a titan in the frenetic development of breast cancer therapies since the mid-late 90s. Dr Brufsky is a Professor of Medicine at the University of Pittsburgh School of Medicine, Chief of the university's Division of Haematology and Oncology and co-director of its Comprehensive Cancer Centre. He received his MD and PhD from the University of Connecticut's School of Medicine in 1990 and has previously worked at Bringham and Women's Hospital and the Dana-Farber Cancer Institute. His areas of special interest include novel therapeutics and management strategies for breast cancer, bone-breast cancer interactions and therapeutics and molecular biology of metastatic breast cancer. He is a font of knowledge and we are so privileged to welcome Dr Brufsky onto the show.
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
On today's blessedly brief episode, Josh and Michael give an overview of one of the greatest challenges for any practicing oncologist: the conundrum of cancer in young people. In recent decades, the number and proportion of young patients diagnosed with colorectal cancer has skyrocketed. This trend has been noted in news outlets across the world, reported in sources as disparate as the New York Times and the Australian Broadcasting Company. From the medical to the logistical and emotional, managing a young person with a cancer diagnosis is very difficult. While neither of our intrepid hosts has an answer to this very complex topic, there are a number of nuggets they drop that could help. Listen on for a thought provoking episode of Oncology for the Inquisitive Mind.
Article discussed in this episode (subscription may be required):
"‘More Young People Than Ever Will Get Colorectal Cancer This Year," by Knuvul Sheikh.
Available from: https://www.nytimes.com/2024/03/27/well/colon-cancer-symptoms-treatment.html?unlocked_article_code=1.gE0.C_DO.__AnqnMB1F4M&smid=nytcore-ios-share&referringSource=articleShare
Art courtesy of Taryn Silver
Audio courtesy of:
Olexy on pixabay: https://pixabay.com/users/olexy-25300778/JuliusH on pixabay: https://pixabay.com/users/juliush-3921568/The opinions discussed in this episode are those of the authors and should not be taken for medical advice. They exist to engender discussion, debate and thought.
Hosted on Acast. See acast.com/privacy for more information.
-
IN BREAKING NEWS... Or not really, as we are a bit late to the party. But in honour of liposomal irinotecan's recent approval by the Federal Drugs Administration, we thought we would take another look at the NAPOLI-3 trial. The first potentially practice-changing update to the treatment of advanced pancreatic cancer arguably in more than a decade, the combination of liposomal irinotecan with 5-fluorouracil and oxaliplatin proved itself superior (spoiler alert) to the established combination of gemcitabine and nab-paclitaxel. Will this practically change practice for our patients? The answer, for Australia at least, is a resounding maybe. Listen on for all the juicy details, and the return of OftiM Newsreader "Walter Fernando-Cronkite."
Links to articles discussed in this episode (subscription may be required):
NAPOLI-3: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01366-1/fulltext
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
It is a tale as old as time, as old as the stars, the heavens and human consciousness itself. Okay, we're exaggerating a bit, but for as long as pharmacology and capitalism have been joined at the hip, the question of "which drug is best" has been at or near the forefront of medical decision-making. With the development of standardised clinical trials and the difficulty of conducting direct head-to-head comparisons, this question has become more difficult to answer conclusively. Nowhere is this epitomised better than with the triptych of available CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib. A lot of ink and pixels have been devoted to comparing the pivotal trials of these three equally pivotal agents: PALOMA-2, MONALEESA-2 and MONARCH-3, respectively. However, Josh and Michael have brought the definitive and not-at-all rambling answer to this question. Listen on to find out!
Links to studies discussed in this episode (subscription may be required):
Review Article (Grinshpun et al.): https://www.nature.com/articles/s41523-023-00520-7
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode, Michael and Josh welcome a very special guest: Michael's Labrador Beans. Beans is a world-renowned expert in eating snacks, but unfortunately, had very little to offer on their topic today: the treatment of progressive or recurrent cutaneous melanoma with primary and secondary resistance to immunotherapy. So, unfortunately, the discussion was left to your regular hosts.
For approximately 50% of patients, this is fortunately not a question they need to worry about, as immunotherapy and BRAF/MEK inhibitors remain effective treatments. However, that still leaves half of all patients facing an uncertain future, as treatment beyond these two agents remains uncertain. Josh and Michael examine two studies that may shine a light in this dark corner of oncology: LEAP-004, a single-arm study of lenvatinib + pembrolizumab, and an article published in the New England Journal of Medicine examining the use of tumour-infiltrating lymphocytes (TILs) as a novel weapon against immunotherapy-resistant melanoma.
Links to studies discussed in this episode (subscription may be required):
LEAP-004: https://ascopubs.org/doi/full/10.1200/JCO.22.00221
Rohaan et al: https://www.nejm.org/doi/full/10.1056/NEJMoa2210233
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
While Josh and Michael enjoy a good rambling, meandering podcast as much as the next guy, we made a promise to keep our coverage of the ASCO GU 2024 conference short and sweet. So, as promised, here is the second - and final - episode of our miniseries. For a change of pace, one of our studies involves the adjuvant use of immunotherapy! Specifically, AMBASSADOR looks at pembrolizumab in patients with early urothelial cancer, a patient cohort that is crying out for more effective treatments for early-stage disease. Meanwhile, Josh tries to "BRCAAway" from our comfort zone by discussing the latest trial examining the use of PARP inhibitors in metastatic castration-resistant prostate cancer. Yes, we'll show ourselves out now.
Links to studies discussed in this episode (subscription may be required):
AMBASSADOR (courtesy of ASCO Daily news): https://ascopost.com/news/january-2024/ambassador-pembrolizumab-in-muscle-invasive-and-locally-advanced-urothelial-carcinoma/#:~:text=AMBASSADOR%20(A031501)%20is%20a%20randomized,and%20locally%20advanced%20urothelial%20carcinoma.
BRCAAway (courtesy of urotoday.com): https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137781-asco-2022-brcaaway-a-randomized-phase-2-trial-of-abiraterone-olaparib-or-abiraterone-olaparib-in-patients-with-mcrpc-with-dna-repair-defects.html
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
With Josh's Grand Adventure(TM) now in the books, he and Michael return to their usual programming, examining two studies presented at the not-so-recent ASCO GU conference in San Fransisco. While the conference took place in January of this year, as the old adage goes: better late than never. In this episode, our hosts examine two studies; the CONTACT-02 study examining a combination of immunotherapy + cabozantinib in patients with metastatic castration-resistant prostate cancer, and an update from the KEYNOTE-564 that examined whether pembrolizumab had any benefit in the adjuvant treatment of renal cell cancer. Will either of these studies change practice? Fear not, for our fearless oncological explorers are on hand to guide you through the hazardous ratios and nefarious p values!
Links to studies discussed in this episode via ASCO Daily News(subscription may be required):
CONTACT-02: https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.18#:~:text=CONTACT%2D02%20is%20the%20only,Clinical%20trial%20information%3A%20NCT04446117.
KEYNOTE-564: https://dailynews.ascopubs.org/do/keynote-564-adjuvant-pembrolizumab-prolongs-survival-high-risk-clear-cell-renal-cell#:~:text=KEYNOTE%2D564%20is%20the%20first,at%20higher%20risk%20for%20recurrence.
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
- もっと表示する
